Peptide Receptor Radionuclide Therapy
Phase 2Small molecule
Peptide Receptor Radionuclide Therapy is one of 12 small molecule programs targeting Carcinoid Syndrome. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Carcinoid Syndrome
#DrugCompanyPhaseTrials
1Lanreotide Acetate
AAlbireo, an Ipsen Company
Phase 3
Lanreotide PRF
IpsenPhase 3
Vectibix
AmgenPhase 2
Dostarlimab
IncytePhase 2
Telotristat Ethyl
LLexicon Pharmaceuticals
Phase 3
Palsonify
CCrinetics Pharmaceuticals Inc.
Phase 3
Octreotide Lar
NovartisPhase 2
Xermelo
TTerSera Therapeutics LLC
Phase 2
Sandostatin
Sun PharmaPhase 1
BIM 23a760
IpsenPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CChandrikha Chandrasekhara